paywalled: Clinical development of new formulations of cytotoxics in so... : Current Opinion in Oncology Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, April 25, 2012

paywalled: Clinical development of new formulations of cytotoxics in so... : Current Opinion in Oncology



Clinical development of new formulations of cytotoxics in so... : Current Opinion in Oncology

Current Opinion in Oncology:
May 2012 - Volume 24 - Issue 3 - p 325–331
doi: 10.1097/CCO.0b013e328351fb29
INNOVATIVE EARLY CLINICAL TRIALS METHODOLOGY AND NEW THERAPEUTICS IN CANCER: Edited by Ahmad Awada

Clinical development of new formulations of cytotoxics in solid tumors


Abstract

Purpose of review: 
To discuss the clinical development of new formulations of old cytotoxic agents and highlight the value of adopting this strategy.

Recent findings: 
Several drugs are currently in clinical development with high potential in improving clinical outcomes compared with their older counterparts. We emphasize on the results of four of these agents, each belonging to a known group of cytotoxics namely amrubicin, EndoTAG-1, pralatrexate and NKTR-102. Each has shown promising results that have the potential in addressing some limitations that have been observed with the ‘earlier generation’ agents.

Summary:  
Improvement in drug development strategies and the appreciation of the mechanisms of action and resistance of the cytotoxic agents currently available in the clinic open the door for developing agents that have the potential of improving clinical outcomes with better safety profiles. It is important to adopt innovative clinical trials designs integrating molecular markers in early clinical development in order to identify the subgroups of patients who would derive the maximal benefit of these novel agents.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.